Antileishmanial activity and immune modulatory effects of benzoxonium chloride and its entrapped forms in niosome on Leishmania tropica

  • Maryam Hakimi Parizi
  • Abbas PardakhtyEmail author
  • Iraj sharifi
  • Saeedeh Farajzadeh
  • Mohammad Hossein Daie Parizi
  • Hamid Sharifi
  • Ali Reza Keyhani
  • Mahshid Mostafavi
  • Mehdi Bamorovat
  • Daryoush Ghaffari
Open Access
Original Article


Benzoxonium chloride is an anti-infective agent that is used as anti-septic drugs for disinfection of the mucus membrane, skin surface and anti-bacterial, and it is also found to be effective against cutaneous leishmaniasis. The present study aims to evaluate the leishmanicidal activity of benzoxonium chloride and niosomal forms against Leishmania tropica stages. Benzoxonium chloride niosomes were prepared by the thin film hydration method and evaluated for morphology, particle size and release study and encapsulation efficiency. This study measured the cytotoxicity, leishmanicidal activity against promastigote and intra macrophage amastigote, apoptosis, and mRNA transcripts by quantitative real time PCR (qPCR) of free solution and niosomal-encapsulated benzoxonium chloride. Span/Tween 60 niosomal formulation of benzoxonium chloride showed superior physical stability and high encapsulation efficiency (96%) than the other forms. Release from the formulations showed that the Span/Tween 60 containing drug had a milder gradient so that 10% of the drug was not released after 4 h. The benzoxonium chloride and niosomal forms inhibited the in vitro growth of promastigote and amastigote forms of L. tropica after 48 h of incubation and represented IC50 values of 90.7 ± 2.7 and 25.4 ± 0.6 μg/ mL, respectively. The rate of apoptosis in niosomal formulations was approximately equal to the positive control (meglumine antimoniate) at the same concentration. Also, an increase in the concentration of this drug reduced the expression of IL-10, but increased the expression of IL-12. The niosomal formulations provided improved anti-leishmanial activities of benzoxonium chloride and played an immunomodulatory role as the mode of action in the treatment of anthroponotic CL.


Niosomal form Benzoxonium chloride Leishmania tropica 


Leishmaniasis refers to a disease that is caused by various Leishmania species. It is a treatable and curable group of diseases that affects some of the poorest people on earth. They are associated with malnutrition, population displacement, poor housing conditions, and weak immune system. Cutaneous leishmaniasis (CL), the most common form, causes skin lesions and it annually affects 0.7–1.2 million people in the Americas, the Mediterranean basin, the Middle East and Central Asia. In 2013, 95% of the cases reported to WHO had occurred in 15 countries (Alvar et al. 2012). In 2014, over 153,000 cases and 138,575 cases in 2015 (new cases and relapse cases) (World Health Organization (WHO) 2016) were reported to WHO from 10 high-burden countries—Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru (World Health Organization (WHO) 2016, 2018).

The clinical management of CL has been based only on treating patients with pentavalent antimonial compounds, which are insufficient, toxic and cause resistance (Yasinzai et al. 2013). The mechanisms of classical drug resistance are often related with lower drug uptake, increased efflux, faster drug metabolism, drug target modifications, and the over-expression of drug transporters. The high prevalence of CL and the appearance of resistance to classical drugs highlight a demand for developing and exploring novel, less toxic, low cost, and more promising therapeutic modalities (Yasinzai et al. 2013).

The topical treatment of CL presents an attractive alternative that avoids the toxicities of parenteral therapy while being administered through a simple painless route. The treatments that have been used topically for leishmaniasis include paromomycin ointment, topical clotrimazole and miconazole, thermotherapy, cryosurgery using CO2 slush, cryotherapy by liquid nitrogen, CO2 laser, and currently liposome of amphotericin B (Singh and Sivakumar 2004; Al-Qubati et al. 2012; Alavi-Naini et al. 2012; Mosimann et al. 2018).

Benzoxonium chloride (C23H42∙ClNO2, Fig. 1) belongs to quaternary ammonium compounds of anti-infective agents that are used as anti-septic drugs and for disinfecting the mucus membrane, skin surface, and medical instruments. Benzoxonium chloride is also effective against bacteria, certain protozoa, yeasts and non-spore forming organisms (Kim et al. 2011). However, studies have suggested that benzoxonium chloride inhibits certain bacterial enzymes ([CSL STYLE ERROR: reference with no printed form.]). In 2015, Thio-Ben was tested in a clinical trial and it evaluated the efficacy of the topical use of tioxolone plus benzoxonium chloride (Thio-Ben) tincture in combination with cryotherapy as compared to intralesional meglumine antimoniate (glucantime™) along with cryotherapy in treating anthroponotic CL (ACL) (Daie Parizi et al. 2015). The study reported that the topical use of Thio-Ben combined with cryotherapy showed good efficacy in treating ACL along with benefits pertaining to more patient compliance and less side effects than intralesional glucantime (Daie Parizi et al. 2015).
Fig. 1

Chemical structure of benzyl-dodecyl-bis (2-hydroxyethyl) azanium;chloride (benzoxonium chloride)

Recently, vesicular drug delivery systems such as phospholipid vesicles (liposomes) have been used in several types of leishmaniasis (Layegh et al. 2011; Balasegaram et al. 2012; Moosavian Kalat et al. 2014). Non-ionic surfactant vesicles (niosomes) have also been tested for the treatment of leishmaniasis (Yasinzai et al. 2013). These are biodegradable, biocompatible, reduce cytotoxicity for animal cells, more stable and relatively inexpensive, and they can be improved via the development of controlled and targeted drug-delivery formulations to overcome resistance (Hu and Rhodes 1999). Given the above mentioned reasons, in this study, we investigated the in vitro effect of benzoxonium chloride and its niosomal forms on Leishmania tropica and also examined the cytotoxicity, apoptosis, and gene expression profiling of the selected formulation.

Materials and methods


Benzoxonium chloride was purchased from BOC Sciences, USA. Meglumine antimoniate (MA, Glucantime®) 1.5 g/5 mL solution was obtained from Sanofi-Aventis, France. MTT powder (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide; Thiazolyl blue), sorbitan esters (Span®), their PEGylated derivatives (Tween®) and cholesterol (CHOL) were provided by Sigma-Aldrich® (USA). DMEM medium with sodium pyruvate, RPMI- 1640 medium with stable glutamine were purchased from Biosera (France) and fetal bovine serum (FBS) were prepared by Gibco (USA). Phycoerythrin (PE) Annexin V Apoptosis Detection Kit I (catalog number: 559763) was prepared by BD Pharmingen™. Phosphate buffered saline (PBS) was purchased from Cassion Lab (USA). Penicillin and streptomycin were obtained from Life Technology (USA) and was frozen at − 20 °C until testing.

Preparation of niosomes

The thin film hydration method was used to prepare the niosomal forms (Pardakhty et al. 2012). Briefly, the nonionic surfactants (Span 60 and 40 and Tween 60 and 40)/CHOL were dissolved in chloroform and mixed at different molar ratios (7:3, 6:4 and 8:2) in a round-bottom flask. The organic solvent was evaporated by a rotary evaporator (Buchi, Switzerland). The hydration of the lipid film was accomplished with 5 mL of deionized water containing 3 mg/mL of benzoxonium chloride in the round-bottom flask at 70 °C for 30 min. The resulting niosomal suspension was then maintained over night at 4 °C and stored in a refrigerator for maturation of the vesicles and further studies.

Characterization of niosomes

The morphology and shape of the vesicles (round multilamellar vesicles; MLVs) and the probable niosomal constituents’ crystallization/separation or aggregation were characterized by optical microscopy (Zeiss, Germany) and micrographs were captured. A particle size analyzer (Malvern Master Sizer 2000 E, UK) was used to measure the average particle size and the particle size distribution. Also, the physical stability of the niosomal formulations was determined by size variations in 3 days, and 1, 3 and 6 months after production (Verma and Stellacci 2010).

Benzoxonium chloride released from the niosomal formulations was studied with an all-glass Franz diffusion cell. An acetate cellulose dialysis membrane (12–14 KD MW cut off, Visking tube, USA) was soaked in deionized (DI) water overnight before the experiment. The receptor compartment was filled with DI water and 1 mL of each formulation was placed on the cellulose acetate membrane. Aliquots of 1 mL were withdrawn at predetermined time intervals of 0, 15, 30, 60, 90, 120, 150, 180 and 240 min and replaced with fresh medium maintained at 37 ± 0.5 °C. The released drug was quantified spectrophotometrically at 208 nm. The mean cumulative drug release level was plotted against time to study the mechanism of drug release in order to compare the release profiles of the different formulae.

For encapsulation efficiency level (EE%), non-entrapped drug was separated from the niosome encapsulated one by centrifugation at 14,000 rpm for 30 min. Three volumes, each of 1 mL isopropyl alcohol, were used to wash the isolated pellets, followed by re-centrifugation under the same conditions to completely remove the non-entrapped drug until a clear solution was obtained. After proper dilution, the benzoxonium chloride concentration was determined spectrophotometrically at 208 nm and analyzed by the following equation: % EE = (Total drug − free drug/Total drug) × 100.

In vitro assays

The cytotoxicity effects of benzoxonium chloride and niosomal forms to evaluate the safety of this compound were checked by MTT assay on J774 A.1 ATCC®TIB-67™ purchased from the Pasteur Institute of Iran with doses between 1.0 and 300.0 μg/mL. In brief, the cultured macrophages (5 × 104) at 37 °C and 5% CO2 were treated with various concentrations of drugs in 96-well tissue culture plates and kept for standard time at 48 h. Routinely, 10 µL of MTT stock solution (5 mg/mL) was added to each well of the tissue culture plates. After incubation for 3 to 4 h, the medium was removed and acidic isopropanol (0.04–0.1 NHCL in absolute isopropanol) was added to stop the reactions. Absorbance was measured by an ELISA reader (BioTek-ELX800 Winooski, Vermont, USA) at a wavelength of 490 nm.

For the promastigote assay, promastigotes of L. tropica (MHOM/IR/2002/Mash2), which was prepared by Leishmaniasis Research Center (Kerman, Iran), in logarithmic growth phase (105cells/mL) were treated with different concentrations of benzoxonium chloride, its niosomal forms or MA alone (positive control) and were evaluated by an MTT assay. Promastigotes without drug and complete medium with no promastigotes and drugs were used as untreated control and blank, respectively. All the treatments were repeated thrice and absorbance was measured at 490 nm.

For the intra-macrophage amastigote assay, 100 μL of macrophage J774A (1 × 105/mL) was added to each slide (75 × 25 mm) in the sterile Petri dish and incubated for 6 h at 37 °C and 5% CO2. The macrophages were then infected at a 1:10 ratio (macrophage: promastigote in stationary phase of L. tropica) and incubated for 24 h at 37 °C, 5% CO2, and 85% relative humidity. After 24 h, drugs concentrations similar to the promastigote assay were added thrice. After confirmation of macrophage infection levels of above 80% (with light microscopy), 100 μL of drugs dilution was added to each slide. The drug and host cell containing amastigotes without drug and complete medium without parasite were considered as untreated control and blank, respectively. After standard time of 48 h at 37 °C for incubation, the slides were stained with Wright Giemsa and the number of amastigotes in 100 macrophages was evaluated by direct observation with an optical microscope. The medium was removed and the slides were fixed with 100% methanol for 2 min and stained by Wright Giemsa for 15 min. The number of amastigotes in 100 macrophages was evaluated for each treatment by direct examination with a light microscope. The dose-response curves and the IC50 values were calculated by using the probit test in SPSS software.

Determination of apoptosis and necrosis

Apoptosis and necrotic cell death were evaluated with PE Annexin V and 7-Amino Actinomycin (7-AAD). Promastigotes of L. tropica (1 × 106) were seeded into the micro tube and treated with the desired concentrations of drugs and incubated at 25 °C for 48 h. After incubation, the promastigotes were washed twice with cold PBS and were suspended in 1 × binding buffer. Then, in a 5-mL culture tube, 5 µL of PE Annexin V and 5 µL of 7-AAD were added and incubated for 15 min in the dark at room temperature. Finally, they were analyzed by flow cytometry (BD FACSCalibur™) within 1 h.

mRNA transcripts and RT-PCR

The levels of expression of IL-10 and IL-12 in macrophage J774A1 and metacaspase genes in the promastigotes of L. tropica were evaluated by a quantitative real-time PCR (q-PCR) assay. RNA was extracted by using the RNeasy mini kit (Qiagen, Chatsworth, CA) from various concentrations of the best selective drug and the untreated control group. The cDNA was made by a first-strand cDNA synthesis kit (Takara Bio, Inc., Shiga, Japan).

The quantitative real time reaction was carried out by the Rotorgene cycler system (Rotorgene 3000 cycler system, Corbett Research, Sydney, Australia) and a SYBR Green experiment (SYBR Premix Ex Taq™ II, Takara, Clontech). GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) for the gene expression of IL-12 and IL-10 in macrophage J774 A and RPS18 Ribosomal protein (S18) for the gene expression of metacaspase in promastigote of L. tropica were used as the reference genes (Table 1) (Chandra and Naik 2008; Satheesh Kumar et al. 2014).
Table 1

Sequences of forward and reverse primers and reference genes used for quantitative real time PCR


Forward sequence (5′–3′)

Reverse sequence (5′–3′)

Product size (bp)









Meta caspase












The cDNA was amplified by 40 three-step cycles (10 s at 95 °C for denaturation of DNA, 15 s at 58 °C for primer annealing, and 20 s at 72 °C for extension).The final temperature was 65 °C for 1 min. The ΔCT was obtained by the following formula: [ΔCT = CT (target) _ CT (reference)]. Gene expression level was specified by the 2−ΔCt method. Also, the fold increase (FI) was calculated by the comparative threshold method (2−ΔΔCT).

Data analysis

The data analysis was performed by using SPSS software version 20 (Chicago, IL, USA). The differences between the groups were assessed by using ANOVA and t test. The 50% inhibitory concentrations (IC50) and dose-response curves were analyzed with probit in SPSS software. P values < 0.05 were regarded as significant. The selectivity indexes were expressed as the ratio between CC50 macrophage/IC50 amastigote forms. The graphs were designed with GRAPHPAD PRISM 6 (Graph Pad Software Inc., San Diego, CA, USA).


Preparation and characterization of niosomes

The prepared niosomes were mostly multilamellar (MLV) round vesicles because we used the lipid film hydration method. Span/Tween 40 (ST40, 7:3 molar ratio, NB1) and Span/Tween 60 (ST60, 6:4 molar ratio, NB2) were chosen as the superior formulations (Fig. 2). Considering that the hydration method of the fatty layer was used in manufacture of niosomes, the diameters of the niosomes were larger than 5 µm. Size analysis of the two formulations showed log-normal particle size distribution curves after 3 days, but NB1 did not have good physical stability as depicted by their widely-changed size distribution curves after 1, 3 and 6 months of storage at refrigerator temperature (Fig. 3). The encapsulation efficiency (more than 96%) was calculated for benzoxonium chloride in the ST40 and ST60 niosomes. The release profile of the niosomal forms of the entrapped material is shown in Fig. 4. The release rate of NB2 was less than NB1 with a milder gradient so that 10% of the drug was not released after 4 h.
Fig. 2

Light microscopy of niosomal forms of benzoxonium chloride ( × 100 magnification) a Span/Tween 40 (7:3 m.r.), b Span/Tween 60 (6:4 m.r.) prepared by film hydration method

Fig. 3

The particle size distribution graph by frequency of a Span Tween 40 (7:3 m.r.) and b Span Tween 60 (6:4 m.r.) after 3 days, 1, 3 and 6 months storage at refrigerator

Fig. 4

The released amount of niosomal forms of benzoxonium chloride (%) at different time intervals (mean ± SD, n = 3)

In vitro assay

According to the survey of cytotoxic assay, there wasn’t any cytotoxicity in the different concentrations used in our study. The 50% inhibitory concentrations (IC50) of promastigote and amastigote treated with the drugs are listed in Table 2. The NB2 formulation showed the most activity as evidenced by the IC50 values of 90.7 ± 2.7 μg/mL and 25.4 ± 0.6 μg/mL for the promastigote and amastigote forms, respectively, after 48 h of incubation. MA showed IC50 of 536.6 ± 40 and 101.8 ± 4.2 μg/mL against the promastigote and amastigote forms, respectively. We observed a dose dependent antileishmanial activity for both forms, as presented in Figs. 5 and 6. The IC50 values of all the drugs demonstrated a significant difference with the positive control (p < 0.001) on the promastigote and amastigote forms, while no significant difference was found between the IC50 rates of NB1and NB2 in the promastigote assay.
Table 2

Antileishmanial activities calculated for benzoxonium chloride (B), niosomal forms (NB1 and NB2) and meglumine antimoniate (MA)






Promastigote IC 50 a (µg/mL)

210.2 ± 6.1

113.1 ± 6.2

90.7 ± 2.7

536.6 ± 40

Amastigote IC 50 a (µg/mL)

147.0 ± 5.4

56.3 ± 1.6

25.4 ± 0.6

101.8 ± 4.2

Data represent the mean value ± standard deviation

a50% inhibitory concentration

Fig. 5

The inhibition of promastigotes in the presence of various concentrations of benzoxonium chloride (B), niosomal forms (NB1 and NB2) and meglumine antimoniate (MA) after 48 h incubation

Fig. 6

The inhibition of amastigotes in the presence of various concentrations of benzoxonium chloride (B), niosomal forms (NB1 and NB2) and meglumine antimoniate (MA) after 48 h incubation

The mean number of amastigotes in 100 macrophages in triplicates is shown in Table 3. Various concentrations of the drugs were able to significantly inhibit the multiplication rate of the amastigotes in each macrophage as compared with the untreated control (P < 0.01).
Table 3

Comparative evaluation of the effect of benzoxonium chloride (B), niosomal forms (NB1 and NB2) and meglumine antimoniate (MA) with untreated control on intramacrophage amastigote of Leishmania tropica






Concentration (µg/µL)

No of amastigote  ± SD

P value

No of amastigote  ± SD

P value

No of amastigote  ± SD

P value

No of amastigote  ± SD

P value

0.00 (control)

60.71 ± 1.46


60.71 ± 1.46


60.71 ± 1.46


60.71 ± 1.46



48.31 ± 0.61


37.03 ± 0.95


35.76 ± 0.32


54.20 ± 1.06



40.2 ± 0.72


33.93 ± 0.70


30.40 ± 0.96


41.86 ± 1.02



34.56 ± 0.58


32.93 ± 0.80


25.56 ± 0.51


34.46 ± 2.05



32.96 ± 0.55


29.03 ± 0.55


20.73 ± 0.64


31.46 ± 1.91



31.42 ± 0.67


24.00 ± 0.90


18.13 ± 0.41


28.16 ± 2.01



30.16 ± 0.86


22.54 ± 0.36


17.23 ± 0.49


22.96 ± 2.62



21.20 ± 0.62


16.83 ± 0.56


20.36 ± 2.51


NR not related

Selectivity Index [SI (Selectivity Index) = CC50 macrophage/IC50 ≥ 10 non-toxic for amastigote forms] was also calculated for the medications, and the highest level was obtained at NB2 (12.5).

Apoptotic cell determination

The levels of apoptotic, necrotic, and viable cells in the closest concentration of each drug to its IC50 dose were determined and compared with the untreated control and similar concentrations with the positive control (MA). The rate of apoptosis in B (200 µg/mL) was very low, while this rate increased significantly in the niosomal formulations. The rate of apoptosis in NB1 (100 µg/mL) and in NB2 (100 µg/mL) was 27.21% and 26.65%, respectively. These values were approximately equal to the positive control (27.4%) at the same concentration. The rate of apoptosis was 0.34% in the untreated control (Fig. 7).
Fig. 7

Flow cytometry analysis demonstrating early and late apoptosis as well as necrotic cells after treatment with the closest concentration of IC50 doses of benzoxonium chloride (B), niosomal forms (NB1 and NB2) and similar concentrations in meglumine antimoniate (MA), after 48 h

RT-PCR analysis

Gene expression in response to L. tropica was evaluated against NB2. The amplification efficiency of each gene was verified by three dilutions (12.5, 50, and 150 µg/mL) (Fig. 8). A comparison of the mean \( 2^{{ - \Delta \Delta {\text{C}}}}_{\text{T}} \) between untreated and treated with NB and MA showed significant changes in mRNA expression of IL-12, IL-10, and the metacaspase genes, except for the concentration of 12.5 µg/mL between untreated and MA (Fig. 8). The mean (±SE) FI when treated with NB (150 µg/mL) for IL-12, IL-10, and metacaspase genes was 11.28 ± 0.18, 0.23 ± 0.05, and 7.02 ± 0.07, respectively. For all the genes at various concentrations, there was a significant difference (P < 0.05) between NB and the positive control (MA).
Fig. 8

Effect of different concentrations of NB2 and positive control (MA) on genes expression of IL-12, IL-10, and metacaspase of L. tropica (comparison between NB and MA with untreated control; P < 0.05*, P < 0.01**, P < 0.001***)


Leishmaniasis is a serious global challenge and all chemical treatments have severe side effects, or there is emerging resistance to these drugs (Ghorbani and Farhoudi 2018). The studies evaluating the drug delivery methods were found to be very promising. Niosomes have potential as new and selective drugs for treating important diseases, including leishmaniasis (Kazi et al. 2010). Previous studies have evaluated the anti-leishmanial effects of Thio-Ben on patients (Daie Parizi et al. 2015) and in the present work, we evaluated the in vitro leishmanicidal effects of benzoxonium chloride (one of the components of Thio-Ben) and its niosomal forms against different forms of the parasite (L. tropica).

Benzoxonium chloride was previously shown to be promising antibacterial, certain antiprotozoal, and anti-septic agents (Kim et al. 2011). Our in vitro studies showed a leishmanicidal activity for the drug and its niosomal forms. Among the tested drugs, the NB2 formulation showed the most potent anti-leishmanial effect against different stages of the parasite by in vitro tests.

Anti-promastigote activity is considered a useful tool for drug evaluation, even though this form of the parasite is only found in the sand fly. The anti-promastigote activities of these drugs were observed. Also, amastigote in clinical stage is responsible for retaining the infection in the mammalian host, the anti-amastigote activity of B and its niosomal forms were evaluated in murine macrophages infected in vitro. A strong anti-amastigote activity was observed in all the tested drugs, as indicated by the significant decrease of intracellular infection. As shown in Table 2 and Figs. 6 and 7, generally all the drugs inhibited the growth of L. tropica promastigotes and amastigotes; although, the NB2 formulation presented the highest antileishmanial activity. The drug selectivity index (SI) of NB2 was higher than the other drugs. Actually, NB2 is 12.5 times safer for the macrophages than for the amastigotes of L. tropica (Almeida-Souza et al. 2018).

A comparison of the various selected niosomal forms revealed that NB2 (Span/Tween 60, 6:4 molar ratio), its size and stability were better than the other formulation (Span/Tween 40, 7:3 molar ratio). The stability of the prepared NB2 was high with no significant changes in the sizes when it was stored at 4 °C for 6 months. Since cholesterol is essential for the formation of niosomes and effects stability, size and shape, therefore, a high content of cholesterol composition in NB2 possibly caused the stability of this formulation (Essa 2010; Kazi et al. 2010). Similarly, in a previous study, the use of Span 60 exhibited lower change in particle size for preparing niosomes containing autoclaved L. major (Pardakhty et al. 2012).

Our results revealed that the effects of the niosomal form of benzoxonium chloride against the promastigote form were partially associated with apoptosis and their rate of apoptosis was equal to the positive control. There is some evidence that apoptosis-like programmed cell death (PCD) has also occurred in some unicellular organisms, such as Leishmania (Besteiro et al. 2007), which could potentially involve metacaspase (Williams et al. 2006). Metacaspase plays a crucial role in the induction of PCD and it is an apoptotic execution switch, and L. major metacaspase can complement an apoptosis cell death phenotype in yeast (González et al. 2007). In our study, the level of metacaspase gene expression increased with increasing drug concentrations (NB), which was significantly higher than the positive control (MA). This increase in the expression level of metacaspase triggers the host’s immune response to Th1 modality. Also, IL-12 is necessary for Th1 polarization and it is crucial for defense against parasitic pathogens that affect the immune response to invading Leishmania parasite. Changes in IL-12 gene expression relative to IL-10 expression t switch cell-mediated immunity toward a Th1 immune response (Martorelli et al. 2012).

In the present study, we demonstrated the ability of niosome of benzoxonium chloride to initiate a Th1 cell-mediated immune response. Actually, with increasing the concentration of this drug, the expression of IL-10 declined and the expression level of IL-12 increased as expected, thereby showing an immunomodulatory role of the drug as the primary mode of action for treating ACL.

The niosomal formulations provided improved and great anti-leishmanial activities of benzoxonium chloride and promoted a protective immune response that provided effective L. tropica elimination with no excessive tissue destruction.



This Project (Protocol No. 94/655) was granted approval by the Leishmaniasis Research Center and received financial support from the Vice Chancellor for Research at the Kerman University of Medical Sciences. This study is a part of a Ph.D. dissertation for pursuit of a Ph.D. by Research degree in Leishmaniasis and skin diseases.

Authors’ contributions

Hakimi Parizi M, Pardakhty A, Sharifi I, Farajzadeh S and Daie Parizi MH designed the experiments. Keyhani AR, Mostafavi M, Bamorovat M, Hakimi Parizi M and Ghaffari D carried out the experimental work. Sharifi H analyzed the data. Hakimi Parizi M wrote the paper. All authors participated in data analysis and interpretation, and read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. Alavi-Naini R, Fazaeli A, O’dempsey T (2012) Topical treatment modalities for old world cutaneous leishmaniasis: a review. Prague Med Rep 113(2):105–118CrossRefGoogle Scholar
  2. Almeida-Souza F, Elisa Reis de Oliveira A, Lucia Abreu-Silva A, da Silva Calabrese K (2018) In vitro activity of Morinda citrifolia Linn. fruit juice against the axenic amastigote form of Leishmania amazonensis and its hydrogen peroxide induction capacity in BALB/c peritoneal macrophages. BMC Res Notes 11:492CrossRefGoogle Scholar
  3. Al-Qubati Y, Janniger EJ, Schwartz RA (2012) Cutaneous leishmaniasis: cryosurgery using carbon dioxide slush in a resource-poor country. Int J Dermatol 51(10):1217–1220CrossRefGoogle Scholar
  4. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7(5):e35671CrossRefGoogle Scholar
  5. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, Milani B, Gaspani S, Potet J, Chappuis F (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17(4):493–510CrossRefGoogle Scholar
  6. Besteiro S, Williams RA, Coombs GH, Mottram JC (2007) Protein turnover and differentiation in Leishmania. Int J Parasitol 37:1063–1075CrossRefGoogle Scholar
  7. Chandra D, Naik S (2008) Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. Clin Exp Immunol 154:224–234CrossRefGoogle Scholar
  8. Benzoxonium chloride drug information | DrugsUpdate India. Cited 16 Apr 2018
  9. Daie Parizi MH, Karvar M, Sharifi I, Bahrampour A, Heshmat Khah A, Rahnama Z, Baziar Z, Amiri R (2015) The topical treatment of anthroponotic cutaneous leishmaniasis with the tincture of thioxolone plus benzoxonium chloride (Thio-Ben) along with cryotherapy: a single-blind randomized clinical trial. Dermatol Ther 28(3):140–146CrossRefGoogle Scholar
  10. Essa E (2010) Effect of formulation and processing variables on the particle size of sorbitan monopalmitate niosomes. Asian J Pharm 4(4):227–233CrossRefGoogle Scholar
  11. Ghorbani M, Farhoudi R (2018) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther 12:25–40CrossRefGoogle Scholar
  12. González IJ, Desponds C, Schaff C, Mottram JC, Fasel N (2007) Leishmania major metacaspase can replace yeast metacaspase in programmed cell death and has arginine-specific cysteine peptidase activity. Int J Parasitol 37(2):161–172CrossRefGoogle Scholar
  13. Hu C, Rhodes DG (1999) Proniosomes: a novel drug carrier preparation. Int J Pharm 185(1):23–35CrossRefGoogle Scholar
  14. Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, Kuotsu K (2010) Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res 1(4):374–380CrossRefGoogle Scholar
  15. Kim BH, Min YS, Choi JS, Baeg GH, Kim Y, Shin JW, Kim TY, Ye SK (2011) Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling. Exp Mol Med 43(5):313–321CrossRefGoogle Scholar
  16. Layegh P, Rajabi O, Jafari MR, Emamgholi Tabar Malekshah P, Moghiman T, Ashraf H, Salari R (2011) Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res 2011:656523CrossRefGoogle Scholar
  17. Martorelli D, Muraro E, Merlo A, Turrini R, Fae DA, Rosato A, Dolcetti R (2012) Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein–Barr-virus-driven disorders. Clin Dev Immunol 3:931952Google Scholar
  18. Moosavian Kalat SA, Khamesipour A, Bavarsad N, Fallah M, Khashayarmanesh Z, Feizi E, Neghabi K, Abbasi A, Jaafari MR (2014) Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice. Exp Parasitol 143:5–10CrossRefGoogle Scholar
  19. Mosimann V, Neumayr A, Paris DH, Blum J (2018) Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: a literature review. Acta Trop 182:246–250CrossRefGoogle Scholar
  20. Pardakhty A, Shakibaie M, Daneshvar H, Khamesipour A, Mohammadi-Khorsand T, Forootanfar H (2012) Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study. J Microencapsul 29(3):219–224CrossRefGoogle Scholar
  21. Satheesh Kumar S, Gokulasuriyan R, Ghosh M (2014) Comparative in-silico genome analysis of Leishmania (Leishmania) donovani: a step towards its species specificity. Meta Gene 2:782–798CrossRefGoogle Scholar
  22. Singh S, Sivakumar R (2004) Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 10:307–315CrossRefGoogle Scholar
  23. Verma A, Stellacci F (2010) Effect of surface properties on nanoparticle–cell interactions. Small 6(1):12–21CrossRefGoogle Scholar
  24. World Health Organization, mondiale de la Santé (2018) Surveillance of leishmaniasis in the WHO European Region, 2016–Surveillance de la leishmaniose dans la Région européenne de l’OMS, 2016. Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire 93(40):521–530Google Scholar
  25. Williams RA, Tetley L, Mottram JC, Coombs GH (2006) Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in Leishmania mexicana. Mol Microbiol 61(3):655–674CrossRefGoogle Scholar
  26. World Health Organization (WHO) (2016) WHO: Weekly epidemiological record Relevé épidémiologique hebdomadaire, no. 83, vol 21. World Health Organization, Geneva, pp 421–428Google Scholar
  27. Yasinzai M, Khan M, Nadhman A, Shahnaz G (2013) Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives. Future Med Chem 5(15):1877–1888CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Maryam Hakimi Parizi
    • 1
  • Abbas Pardakhty
    • 2
    Email author
  • Iraj sharifi
    • 1
  • Saeedeh Farajzadeh
    • 3
  • Mohammad Hossein Daie Parizi
    • 4
  • Hamid Sharifi
    • 5
  • Ali Reza Keyhani
    • 1
  • Mahshid Mostafavi
    • 1
  • Mehdi Bamorovat
    • 6
  • Daryoush Ghaffari
    • 1
  1. 1.Leishmaniasis Research CenterKerman University of Medical SciencesKermanIran
  2. 2.Pharmaceutics Research Center, Neuropharmacology InstituteKerman University of Medical SciencesKermanIran
  3. 3.Department of Pediatric DermatologyKerman University of Medical SciencesKermanIran
  4. 4.Department of PediatricsKerman University of Medical SciencesKermanIran
  5. 5.HIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in HealthKerman University of Medical SciencesKermanIran
  6. 6.Research Center of Tropical and Infectious DiseasesKerman University of Medical SciencesKermanIran

Personalised recommendations